FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Manfred Volm

Research Profile

Disorders

Physiology

Procedures

Chemicals & Drugs

Living Beings

Anatomy

Tumor Cells, Cultured

Co-author Network

Publications

TOP 3
Theodor H Lippert; Hans-Jörg Ruoff; Manfred Volm
Current status of methods to assess cancer drug resistance.
Alexei V Salnikov; Jury Gladkich; Gerhard Moldenhauer; Manfred Volm; Jürgen Mattern; Ingrid Herr
CD133 is indicative for a resistance phenotype but does not represent a prognostic marker for survival of non-small cell lung cancer patients.
Thomas Efferth; Badireenath Konkimalla; Yi-Fen Wang; Axel Sauerbrey; Silke Meinhardt; Felix Zintl; Jürgen Mattern; Manfred Volm
Prediction of broad spectrum resistance of tumors towards anticancer drugs.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Manfred Volm (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2011: Theodor H Lippert; Hans-Jörg Ruoff; Manfred Volm
Current status of methods to assess cancer drug resistance.
International journal of medical sciences 2011;8(3):245-53.
2010: Alexei V Salnikov; Jury Gladkich; Gerhard Moldenhauer; Manfred Volm; Jürgen Mattern; Ingrid Herr
CD133 is indicative for a resistance phenotype but does not represent a prognostic marker for survival of non-small cell lung cancer patients.
International journal of cancer. Journal international du cancer 2010;126(4):950-8.
2008: Thomas Efferth; Badireenath Konkimalla; Yi-Fen Wang; Axel Sauerbrey; Silke Meinhardt; Felix Zintl; Jürgen Mattern; Manfred Volm
Prediction of broad spectrum resistance of tumors towards anticancer drugs.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(8):2405-12.
2008: Theodor H Lippert; Hans-Jörg Ruoff; Manfred Volm
Intrinsic and acquired drug resistance in malignant tumors. The main reason for therapeutic failure.
Arzneimittel-Forschung 2008;58(6):261-4.
2008: Theodor Hermann Lippert; Hans-Jörg Ruoff; Manfred Volm
Resistance in malignant tumors: can resistance assays optimize cytostatic chemotherapy?
Pharmacology 2008;81(3):196-203.
2005: Thomas Efferth; Manfred Volm
Pharmacogenetics for individualized cancer chemotherapy.
Pharmacology & therapeutics 2005;107(2):155-76.
2005: Thomas Efferth; Manfred Volm
Glutathione-related enzymes contribute to resistance of tumor cells and low toxicity in normal organs to artesunate.
In vivo (Athens, Greece) 2005;19(1):225-32.
2004: Jürgen Mattern; Manfred Volm
Imbalance of cell proliferation and apoptosis during progression of lung carcinomas.
Anticancer research 2004;24(6):4243-6.
2003: Thomas Efferth; Axel Sauerbrey; Armin Olbrich; Erich Gebhart; Pia Rauch; H Oliver Weber; Jan G Hengstler; Marc-Eric Halatsch; Manfred Volm; Kenneth D Tew; Douglas Ross; Jens Oliver Funk
Molecular modes of action of artesunate in tumor cell lines.
Molecular pharmacology 2003;64(2):382-94.
2003: Manfred Volm; Reet Koomägi
Prognostic relevance of angiogenic, proliferative, and apoptotic factors in lung carcinomas. A case review.
Methods in molecular medicine 2003;74():269-82.
2003: Manfred Volm; Reet Koomägi; Werner Rittgen
Cellular predictive factors of drug resistance in non-small cell lung carcinomas.
Methods in molecular medicine 2003;75():39-51.
2002: Jürgen Mattern; Reet Koomägi; Manfred Volm
Expression of drug resistance gene products during progression of lung carcinomas.
Oncology reports 2002;9(6):1181-4.
2002: Manfred Volm; Axel Sauerbrey; F Zintl; Reet Koomägi; Thomas Efferth
Protein expression profile of newly diagnosed acute lymphoblastic leukemia in children developing relapses.
Oncology reports 2002;9(5):965-9.
2002: Manfred Volm; Reet Koomägi; Jürgen Mattern; T Efferth
Protein expression profiles indicative for drug resistance of non-small cell lung cancer.
British journal of cancer 2002;87(3):251-7.
2002: Manfred Volm; Reet Koomägi; Thomas Efferth; Jürgen Mattern
Protein expression profiles of non-small cell lung carcinomas: correlation with histological subtype.
Anticancer research 2002;22(4):2321-4.
2002: Manfred Volm; Reet Koomägi; Jürgen Mattern; Thomas Efferth
Expression profile of genes in non-small cell lung carcinomas from long-term surviving patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(6):1843-8.
2002: Jürgen Mattern; Reet Koomägi; Manfred Volm
Characteristics of long-term survivors of untreated lung cancer.
Lung cancer (Amsterdam, Netherlands) 2002;36(3):277-82.
2002: Thomas Efferth; Reet Koomägi; Jürgen Mattern; Manfred Volm
Expression profile of proteins involved in the xenotransplantability of non-small cell lung cancers into athymic nude mice.
International journal of oncology 2002;20(2):391-5.
2002: Ulrike Masanek; Gerd Stammler; Manfred Volm
Modulation of multidrug resistance in human ovarian cancer cell lines by inhibition of P-glycoprotein 170 and PKC isoenzymes with antisense oligonucleotides.
Journal of experimental therapeutics & oncology 2002;2(1):37-41.
2002: Manfred Volm; Reet Koomägi; Jürgen Mattern; Thomas Efferth
Protein expression profile of primary human squamous cell lung carcinomas indicative of the incidence of metastases.
Clinical & experimental metastasis 2002;19(5):385-90.
2001: Jürgen Mattern; Manfred Volm
Clinical estimation of the growth rate of lung cancer.
Anticancer research 2001;21(6A):4067-70.
2001: R Koomagi; Felix Zintl; Axel Sauerbrey; Manfred Volm
Vascular endothelial growth factor in newly diagnosed and recurrent childhood acute lymphoblastic leukemia as measured by real-time quantitative polymerase chain reaction.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(11):3381-4.
2000: Manfred Volm; Werner Rittgen
Cellular predictive factors for the drug response of lung cancer.
Anticancer research 2000;20(5B):3449-58.
2000: Manfred Volm; Jürgen Mattern; Reet Koomägi
Angiostatin expression in non-small cell lung cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(8):3236-40.
2000: Manfred Volm; Reet Koomägi
Hypoxia-inducible factor (HIF-1) and its relationship to apoptosis and proliferation in lung cancer.
Anticancer research 2000;20(3A):1527-33.
2000: Manfred Volm; Reet Koomägi
Relevance of proliferative and pro-apoptotic factors in non-small-cell lung cancer for patient survival.
British journal of cancer 2000;82(10):1747-54.
2000: Reet Koomägi; Manfred Volm
Relationship between the expression of caspase-3 and the clinical outcome of patients with non-small cell lung cancer.
Anticancer research 2000;20(1B):493-6.
2000: Manfred Volm; R Koomagi
Prognostic relevance of c-Myc and caspase-3 for patients with non-small cell lung cancer.
Oncology reports 2000;7(1):95-8.
2000: Manfred Volm; Jürgen Mattern; Reet Koomägi
Association of telomerase expression with successful heterotransplantation of lung cancer.
International journal of oncology 2000;16(1):31-5.
1999: Reet Koomägi; Jürgen Mattern; Manfred Volm
Glucose-related protein (GRP78) and its relationship to the drug-resistance proteins P170, GST-pi, LRP56 and angiogenesis in non-small cell lung carcinomas.
Anticancer research 1999;19(5B):4333-6.
1999: Manfred Volm; Felix Zintl; Axel Sauerbrey; Reet Koomägi
Proliferation and apoptosis in newly diagnosed and relapsed childhood acute lymphoblastic leukemia.
Anticancer research 1999;19(5B):4327-31.
1999: Manfred Volm; Felix Zintl; Axel Sauerbrey; Reet Koomägi
Expression of Fas ligand in newly diagnosed childhood acute lymphoblastic leukemia.
Anticancer research 1999;19(4C):3399-402.
1999: Manfred Volm; Reet Koomägi
Association of cyclin D1 expression in lung cancer and the smoking habits of patients.
Cancer letters 1999;141(1-2):147-50.
1999: Reet Koomägi; Manfred Volm
Expression of Fas (CD95/APO-1) and Fas ligand in lung cancer, its prognostic and predictive relevance.
International journal of cancer. Journal international du cancer 1999;84(3):239-43.
1999: Jürgen Mattern; Reet Koomägi; Manfred Volm
Biological characterization of subgroups of squamous cell lung carcinomas.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(6):1459-63.
1999: Jürgen Mattern; Reet Koomägi; Manfred Volm
Xenotransplantability of human squamous cell lung cancer in nude mice is not affected by angiogenic factors.
Anticancer research 1999;19(3A):1941-3.
1999: Manfred Volm; Jürgen Mattern; Reet Koomägi
Inverse correlation between apoptotic (Fas ligand, caspase-3) and angiogenic factors (VEGF, microvessel density) in squamous cell lung carcinomas.
Anticancer research 1999;19(3A):1669-71.
1999: Manfred Volm; Jürgen Mattern; R Koomagi
Relationship of urokinase and urokinase receptor in non-small cell lung cancer to proliferation, angiogenesis, metastasis and patient survival.
Oncology reports 1999;6(3):611-5.
1999: Manfred Volm; R Koomagi
The implications of proliferation and apoptosis for lung cancer metastasis.
Oncology reports 1999;6(2):373-6.
1999: Manfred Volm; Reet Koomägi; Jürgen Mattern
Angiogenesis and cigarette smoking in squamous cell lung carcinomas: an immunohistochemical study of 28 cases.
Anticancer research 1999;19(1A):333-6.
1999: Manfred Volm; Reet Koomägi; Jürgen Mattern
PD-ECGF, bFGF, and VEGF expression in non-small cell lung carcinomas and their association with lymph node metastasis.
Anticancer research 1999;19(1B):651-5.
1998: Jürgen Mattern; Reet Koomägi; Manfred Volm
Xenotransplantability of human cancers in mice.
Journal of the National Cancer Institute 1998;90(22):1747-9.
1998: Reet Koomägi; Axel Sauerbrey; Felix Zintl; Manfred Volm
nm23-H1 protein expression in newly diagnosed and relapsed childhood acute lymphoblastic leukemia.
Anticancer research 1998;18(6A):4307-9.
1998: Manfred Volm; Jürgen Mattern; R Koomagi
Expression of platelet-derived endothelial cell growth factor in non-small cell lung carcinomas: relationship to various biological factors.
International journal of oncology 1998;13(5):975-9.
1998: Manfred Volm; Jürgen Mattern; Reet Koomägi
Association between nm23-H1 expression, proliferation and apoptosis in non-small cell lung carcinomas.
Clinical & experimental metastasis 1998;16(7):595-602.
1998: Jürgen Mattern; Uta Eichhorn; Bernd Kaina; Manfred Volm
O6-methylguanine-DNA methyltransferase activity and sensitivity to cyclophosphamide and cisplatin in human lung tumor xenografts.
International journal of cancer. Journal international du cancer 1998;77(6):919-22.
1998: Manfred Volm
Multidrug resistance and its reversal.
Anticancer research 1998;18(4C):2905-17.
1998: Manfred Volm; Reet Koomägi; Jürgen Mattern
Prognostic value of p16INK4A expression in lung adenocarcinoma.
Anticancer research 1998;18(4A):2309-12.
1998: Jürgen Mattern; Reet Koomägi; Manfred Volm
Smoking-related increase of O6-methylguanine-DNA methyltransferase expression in human lung carcinomas.
Carcinogenesis 1998;19(7):1247-50.
1998: Manfred Volm; Reet Koomägi; Werner Rittgen
Clinical implications of cyclins, cyclin-dependent kinases, RB and E2F1 in squamous-cell lung carcinoma.
International journal of cancer. Journal international du cancer 1998;79(3):294-9.
1998: Reet Koomägi; Manfred Volm
Tissue-factor expression in human non-small-cell lung carcinoma measured by immunohistochemistry: correlation between tissue factor and angiogenesis.
International journal of cancer. Journal international du cancer 1998;79(1):19-22.
1998: Manfred Volm; Werner Rittgen; Peter Drings
Prognostic value of ERBB-1, VEGF, cyclin A, FOS, JUN and MYC in patients with squamous cell lung carcinomas.
British journal of cancer 1998;77(4):663-9.
1998: Jürgen Mattern; Gerd Stammler; R Koomagi; Diethelm Wallwiener; M Kaufmann; Manfred Volm
Spontaneous apoptosis in ovarian cancer: an unfavorable prognostic factor.
International journal of oncology 1998;12(2):351-4.
1997: Manfred Volm; Jürgen Mattern; Reet Koomägi
Expression of lung resistance-related protein (LRP) in non-small cell lung carcinomas of smokers and non-smokers and its predictive value for doxorubicin resistance.
Anti-cancer drugs 1997;8(10):931-6.
1997: Manfred Volm; Reet Koomägi; Gerd Stammler; Werner Rittgen; Felix Zintl; Axel Sauerbrey
Prognostic implications of cyclins (D1, E, A), cyclin-dependent kinases (CDK2, CDK4) and tumor-suppressor genes (pRB, p16INK4A) in childhood acute lymphoblastic leukemia.
International journal of cancer. Journal international du cancer 1997;74(5):508-12.
1997: Manfred Volm; Gerd Stammler; Felix Zintl; Reet Koomägi; Axel Sauerbrey
Expression of lung resistance-related protein (LRP) in initial and relapsed childhood acute lymphoblastic leukemia.
Anti-cancer drugs 1997;8(7):662-5.
1997: Gerd Stammler; Felix Zintl; Axel Sauerbrey; Manfred Volm
Deoxycytidine kinase mRNA expression in childhood acute lymphoblastic leukemia.
Anti-cancer drugs 1997;8(5):517-21.
1997: Jürgen Mattern; Reet Koomägi; Manfred Volm
Coexpression of VEGF and bFGF in human epidermoid lung carcinoma is associated with increased vessel density.
Anticancer research 1997;17(3C):2249-52.
1997: Manfred Volm; Reet Koomägi; Jürgen Mattern; Gerd Stammler
Prognostic value of basic fibroblast growth factor and its receptor (FGFR-1) in patients with non-small cell lung carcinomas.
European journal of cancer (Oxford, England : 1990) 1997;33(4):691-3.
1997: Gerd Stammler; Manfred Volm
Green tea catechins (EGCG and EGC) have modulating effects on the activity of doxorubicin in drug-resistant cell lines.
Anti-cancer drugs 1997;8(3):265-8.
1997: Manfred Volm; Reet Koomägi; Jürgen Mattern
Prognostic value of vascular endothelial growth factor and its receptor Flt-1 in squamous cell lung cancer.
International journal of cancer. Journal international du cancer 1997;74(1):64-8.
1997: U Masanek; Gerd Stammler; Manfred Volm
Messenger RNA expression of resistance proteins and related factors in human ovarian carcinoma cell lines resistant to doxorubicin, taxol and cisplatin.
Anti-cancer drugs 1997;8(2):189-98.
1997: Manfred Volm; Felix Zintl; L Edler; Axel Sauerbrey
Prognostic value of protein kinase C, proto-oncogene products and resistance-related proteins in newly diagnosed childhood acute lymphoblastic leukemia.
Medical and pediatric oncology 1997;28(2):117-26.
1997: Gerd Stammler; Axel Sauerbrey; Felix Zintl; Manfred Volm
Apoptotic index, Fas and bcl-2 in initial and relapsed childhood acute lymphoblastic leukaemia.
Apoptosis : an international journal on programmed cell death 1997;2(4):377-83.
1997: Manfred Volm; Reet Koomägi; Jürgen Mattern; Gerd Stammler
Cyclin A is associated with an unfavourable outcome in patients with non-small-cell lung carcinomas.
British journal of cancer 1997;75(12):1774-8.
1997: Manfred Volm; Reet Koomägi; Jürgen Mattern; Gerd Stammler
Angiogenic growth factors and their receptors in non-small cell lung carcinomas and their relationships to drug response in vitro.
Anticancer research 1997;17(1A):99-103.
1997: Jürgen Mattern; Gerd Stammler; R Koomagi; Diethelm Wallwiener; M Kaufmann; Manfred Volm
Association of vascular endothelial growth factor expression with tumor cell proliferation in ovarian carcinoma.
Anticancer research 1997;17(1B):621-4.
1996: Reet Koomägi; Gerd Stammler; C Manegold; Jürgen Mattern; Manfred Volm
Expression of resistance-related proteins in tumoral and peritumoral tissues of patients with lung cancer.
Cancer letters 1996;110(1-2):129-36.
1996: Jürgen Mattern; Friedrich Kallinowski; Christian Herfarth; Manfred Volm
Association of resistance-related protein expression with poor vascularization and low levels of oxygen in human rectal cancer.
International journal of cancer. Journal international du cancer 1996;67(1):20-3.
1996: Manfred Volm; R Koomagi; M Kaufmann; Jürgen Mattern; Gerd Stammler
Microvessel density, expression of proto-oncogenes, resistance-related proteins and incidence of metastases in primary ovarian carcinomas.
Clinical & experimental metastasis 1996;14(3):209-14.
1996: Jürgen Mattern; Reet Koomägi; Manfred Volm
Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumour cell proliferation in human epidermoid lung carcinoma.
British journal of cancer 1996;73(7):931-4.
1996: Manfred Volm; Reet Koomägi; G van Kaick; Jürgen Mattern
[Vascular thickness and cytostatic-resistant bronchial carcinoma].
Deutsche medizinische Wochenschrift (1946) 1996;121(10):291-4.
1996: Manfred Volm; Gerd Stammler
Retinoblastoma (Rb) protein expression and resistance in squamous cell lung carcinomas.
Anticancer research 1996;16(2):891-4.
1996: Gerd Stammler; Manfred Volm
Expression of heat shock proteins, glutathione peroxidase and catalase in childhood acute lymphoblastic leukemia and nephroblastoma.
Cancer letters 1996;99(1):35-42.
1996: Gerd Stammler; E W Pommerenke; U Masanek; Jürgen Mattern; Manfred Volm
Messenger RNA expression of resistance factors in human tumor cell lines after single exposure to radiation.
Journal of experimental therapeutics & oncology 1996;1(1):39-48.
1996: Manfred Volm; Jürgen Mattern
Resistance mechanisms and their regulation in lung cancer.
Critical reviews in oncogenesis 1996;7(3-4):227-44.
1996: Manfred Volm; Reet Koomägi; Jürgen Mattern
Interrelationships between microvessel density, expression of VEGF and resistance to doxorubicin of non-small lung cell carcinoma.
Anticancer research 1996;16(1):213-7.
1995: Manfred Volm; Jürgen Mattern; Gerd Stammler
Up-regulation of heat shock protein 70 in adenocarcinomas of the lung in smokers.
Anticancer research 1995;15(6B):2607-9.
1995: Manfred Volm; Jürgen Mattern; Gerd Stammler; Brigitte Royer-Pokora; S Schneider; Angela Weirich; R Ludwig
Expression of resistance-related proteins in nephroblastoma after chemotherapy.
International journal of cancer. Journal international du cancer 1995;63(2):193-7.
1995: Gerd Stammler; E W Pommerenke; Jürgen Mattern; Manfred Volm
Effects of single doses of irradiation on the expression of resistance-related proteins in murine NIH 3T3 and human lung carcinoma cells.
Carcinogenesis 1995;16(9):2051-5.
1995: Manfred Volm; Reet Koomägi; Jürgen Mattern; Gerd Stammler
Heat shock (hsp70) and resistance proteins in non-small cell lung carcinomas.
Cancer letters 1995;95(1-2):195-200.
1995: Manfred Volm; S Hecker; Axel Sauerbrey; Jürgen Mattern
Predictive value of statin, a G0-associated cell cycle protein, in childhood acute lymphoblastic leukemia.
International journal of cancer. Journal international du cancer 1995;64(3):166-70.
1995: Jürgen Mattern; Axel Sauerbrey; Manfred Volm
p53 protein detected by two different antibodies: relationship to proliferation and prognosis in acute lymphoblastic leukemia.
Anticancer research 1995;15(3):1043-7.
1995: Manfred Volm; E W Pommerenke
Associated expression of protein kinase C with resistance to doxorubicin in human lung cancer.
Anticancer research 1995;15(2):463-6.
1995: E W Pommerenke; Manfred Volm
Reversal of doxorubicin-resistance in solid tumors by clomipramine.
In vivo (Athens, Greece) 1995;9(2):99-101.
1995: Gerd Stammler; Axel Sauerbrey; Manfred Volm
Messenger RNA expression of resistance factors and their correlation to the proliferative activity in childhood acute lymphoblastic leukemia.
Cancer letters 1995;89(1):129-35.
1994: S Hecker; Axel Sauerbrey; Manfred Volm
p53 expression and poor prognosis in childhood acute lymphoblastic leukemia.
Anticancer research 1994;14(6B):2759-61.
1994: Gerd Stammler; Axel Sauerbrey; Manfred Volm
Determination of DNA topoisomerase II in newly diagnosed childhood acute lymphoblastic leukemia by immunocytochemistry and RT-PCR.
Cancer letters 1994;84(2):141-7.
1994: Axel Sauerbrey; Felix Zintl; Manfred Volm
Expression of metallothionein in initial and relapsed childhood acute lymphoblastic leukemia.
Annals of hematology 1994;69(3):111-5.
1994: Manfred Volm; G van Kaick; Jürgen Mattern
Analysis of c-fos, c-jun, c-erbB1, c-erbB2 and c-myc in primary lung carcinomas and their lymph node metastases.
Clinical & experimental metastasis 1994;12(4):329-34.
1994: Manfred Volm; Axel Sauerbrey; Felix Zintl
Dihydrofolate-reductase and thymidylate-synthase in childhood acute lymphoblastic leukemia.
Anticancer research 1994;14(3B):1377-81.
1994: Manfred Volm; Felix Zintl; Axel Sauerbrey
Thymidylate synthase in childhood acute non-lymphoblastic leukemia.
Anticancer research 1994;14(3B):1271-5.
1994: Manfred Volm; T Efferth
[Overcoming resistance in tumors].
Deutsche medizinische Wochenschrift (1946) 1994;119(13):475-9.
1994: Jürgen Mattern; Manfred Volm
Detection of resistance proteins in matched primary lung tumors and lymph node metastases.
Anticancer research 1994;14(2A):417-9.
1994: E Pommerenke; Jürgen Mattern; Manfred Volm
Modulation of doxorubicin-toxicity by tamoxifen in multidrug-resistant tumor cells in vitro and in vivo.
Journal of cancer research and clinical oncology 1994;120(7):422-6.
1993: Manfred Volm; Jürgen Mattern
Correlation between successful heterotransplantation of lung tumors in nude mice, poor prognosis of patients and expression of Fos, Jun, ErbB1, and Ras.
Anticancer research 1993;13(6A):2021-5.
1993: T Efferth; Manfred Volm
Increase of alkaline phosphatase in multidrug-resistant tumor cells and their cross-resistance to 6-thioguanine.
Arzneimittel-Forschung 1993;43(10):1118-21.
1993: T Efferth; Manfred Volm
Reversal of doxorubicin-resistance in sarcoma 180 tumor cells by inhibition of different resistance mechanisms.
Cancer letters 1993;70(3):197-202.
1993: T Efferth; T A Dunn; M Berlion; H Langenbahn; E W Pommerenke; Manfred Volm
Reversal of inherent multidrug-resistance in primary human renal cell carcinoma cell cultures by S 9788.
Anticancer research 1993;13(4):905-8.
1993: Manfred Volm; P Drings; W Wodrich; G van Kaick
Expression of oncoproteins in primary human non-small cell lung cancer and incidence of metastases.
Clinical & experimental metastasis 1993;11(4):325-9.
1993: T Efferth; Manfred Volm
Modulation of P-glycoprotein-mediated multidrug resistance by monoclonal antibodies, immunotoxins or antisense oligodeoxynucleotides in kidney carcinoma and normal kidney cells.
Oncology 1993;50(4):303-8.
1993: Manfred Volm; M Kästel; Jürgen Mattern; T Efferth
Expression of resistance factors (P-glycoprotein, glutathione S-transferase-pi, and topoisomerase II) and their interrelationship to proto-oncogene products in renal cell carcinomas.
Cancer 1993;71(12):3981-7.
1993: W Wodrich; Manfred Volm
Overexpression of oncoproteins in non-small cell lung carcinomas of smokers.
Carcinogenesis 1993;14(6):1121-4.
1993: Manfred Volm
P-glycoprotein associated expression of c-fos and c-jun products in human lung carcinomas.
Anticancer research 1993;13(2):375-8.
1993: Manfred Volm; P Drings; W Wodrich
Prognostic significance of the expression of c-fos, c-jun and c-erbB-1 oncogene products in human squamous cell lung carcinomas.
Journal of cancer research and clinical oncology 1993;119(9):507-10.
1992: T Efferth; Manfred Volm
Expression of protein kinase C in human renal cell carcinoma cells with inherent resistance to doxorubicin.
Anticancer research 1992;12(6B):2209-11.
1992: Manfred Volm; Jürgen Mattern
Elevated expression of thymidylate synthase in doxorubicin resistant human non small cell lung carcinomas.
Anticancer research 1992;12(6B):2293-6.
1992: Manfred Volm; Jürgen Mattern
Expression of topoisomerase II, catalase, metallothionein and thymidylate-synthase in human squamous cell lung carcinomas and their correlation with doxorubicin resistance and with patients' smoking habits.
Carcinogenesis 1992;13(11):1947-50.
1992: Jürgen Mattern; Manfred Volm
[The individualized therapy of tumors].
Deutsche medizinische Wochenschrift (1946) 1992;117(44):1685-9.
1992: Manfred Volm; T Efferth; Jürgen Mattern; E W Pommerenke
Resistance mechanisms in murine tumors with acquired multidrug resistance.
Arzneimittel-Forschung 1992;42(9):1163-8.
1992: Manfred Volm; Jürgen Mattern; B Samsel
Relationship of inherent resistance to doxorubicin, proliferative activity and expression of P-glycoprotein 170, and glutathione S-transferase-pi in human lung tumors.
Cancer 1992;70(4):764-9.
1992: Manfred Volm; Jürgen Mattern; T Efferth; E W Pommerenke
Expression of several resistance mechanisms in untreated human kidney and lung carcinomas.
Anticancer research 1992;12(4):1063-7.
1992: Jürgen Mattern; Manfred Volm
Prediction of drug resistance in human tumors using immunohistochemical techniques.
Anticancer research 1992;12(2):413-8.
1992: T Efferth; Manfred Volm
Immunocytochemical detection of oncoproteins in animal and human tumor lines with acquired or inherent multidrug resistance.
Cancer detection and prevention 1992;16(4):237-43.
1992: T Efferth; Jürgen Mattern; Manfred Volm
Immunohistochemical detection of P glycoprotein, glutathione S transferase and DNA topoisomerase II in human tumors.
Oncology 1992;49(5):368-75.
1992: Manfred Volm; T Efferth; Jürgen Mattern
Oncoprotein (c-myc, c-erbB1, c-erbB2, c-fos) and suppressor gene product (p53) expression in squamous cell carcinomas of the lung. Clinical and biological correlations.
Anticancer research 1992;12(1):11-20.
1991: Manfred Volm; Jürgen Mattern; B Samsel
Overexpression of P-glycoprotein and glutathione S-transferase-pi in resistant non-small cell lung carcinomas of smokers.
British journal of cancer 1991;64(4):700-4.
1991: Manfred Volm; Jürgen Mattern; B Samsel
[The prevalence of cytostatic-resistant lung tumors in smokers].
Deutsche medizinische Wochenschrift (1946) 1991;116(35):1303-6.
1991: E W Pommerenke; Jürgen Mattern; U Traugott; Manfred Volm
[Reversal of multidrug resistance with (R)-verapamil in vitro and in vivo].
Arzneimittel-Forschung 1991;41(8):855-8.
1991: T Efferth; B Lathan; Manfred Volm
Selective growth-inhibition of multidrug-resistant CHO-cells by the monoclonal antibody 265/F4.
British journal of cancer 1991;64(1):87-9.
1991: Manfred Volm; E W Pommerenke; T Efferth; H Löhrke; Jürgen Mattern
Circumvention of multi-drug resistance in human kidney and kidney carcinoma in vitro.
Cancer 1991;67(10):2484-9.
1991: T Efferth; T Klett; Jürgen Mattern; H Osswald; E W Pommerenke; M Stöhr; Manfred Volm
Reversing multidrug resistance in L1210 tumor cells by hycanthone or chlorophenoxamine in vitro and in vivo.
Anticancer research 1991;11(3):1275-9.
1991: Manfred Volm; Jürgen Mattern; E W Pommerenke
Time course of MDR gene amplification during in vivo selection for doxorubicin-resistance and during reversal in murine leukemia L 1210.
Anticancer research 1991;11(2):579-85.
1990: E W Pommerenke; H Osswald; Eric W Hahn; Manfred Volm
Activity of various amphiphilic agents in reversing multidrug resistance of L 1210 cells.
Cancer letters 1990;55(1):17-23.
1990: Manfred Volm; B Samsel; Jürgen Mattern
Relationship between chemoresistance of lung tumours and cigarette smoking.
British journal of cancer 1990;62(2):255-6.
1990: J Schneider; L Edler; W Kleine; Manfred Volm
DNA analysis, chemoresistance testing and hormone receptor levels as prognostic factors in advanced ovarian carcinoma.
Archives of gynecology and obstetrics 1990;248(1):45-52.
1990: T Efferth; H Löhrke; Manfred Volm
Correlations between natural resistance to doxorubicin, proliferative activity, and expression of P-glycoprotein 170 in human kidney tumor cell lines.
Urological research 1990;18(5):309-12.
1990: Manfred Volm; T Efferth
Relationship of DNA ploidy to chemoresistance of tumors as measured by in vitro tests.
Cytometry 1990;11(3):406-10.
1990: Jürgen Mattern; M Bak; Manfred Volm
Intrinsic and acquired multidrug resistance in human lung carcinomas grown in nude mice.
Anticancer research 1990;10(1):177-80.
1990: Manfred Volm; Heide Zerban; Jürgen Mattern; T Efferth
Overexpression of P-glycoprotein in rat hepatocellular carcinomas induced with N-nitrosomorpholine.
Carcinogenesis 1990;11(1):169-72.
1989: Jürgen Mattern; M Bak; K H Hoever; Manfred Volm
Radiosensitivity of drug-resistant human tumour xenografts.
Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al] 1989;165(12):870-2.
1989: J Schneider; M Bak; T Efferth; M Kaufmann; Jürgen Mattern; Manfred Volm
P-glycoprotein expression in treated and untreated human breast cancer.
British journal of cancer 1989;60(6):815-8.
1989: Jürgen Mattern; Manfred Volm
[P glycoprotein as a resistance marker in tumors].
Deutsche medizinische Wochenschrift (1946) 1989;114(50):1979-81.
1989: T Efferth; H Löhrke; Manfred Volm
Reciprocal correlation between expression of P-glycoprotein and accumulation of rhodamine 123 in human tumors.
Anticancer research 1989;9(6):1633-7.
1989: Manfred Volm; W Kleine; A Pfleiderer
Flow-cytometric prognostic factors for the survival of patients with ovarian carcinoma: a 5-year follow-up study.
Gynecologic oncology 1989;35(1):84-9.
1989: Manfred Volm; T Efferth; Jürgen Mattern
Acquired drug resistance in human lung carcinoma xenografts.
Arzneimittel-Forschung 1989;39(8):828-31.
1989: Manfred Volm; K Kayser; Jürgen Mattern
[Demonstration of independent cellular prognostic factors in squamous cell carcinoma of the lung].
Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al] 1989;165(8):587-92.
1989: Jürgen Mattern; L Edler; Manfred Volm
Quantitative analysis of resistance and cross-resistance to cytotoxic agents by tumour cell lines.
Anticancer research 1989;9(4):833-6.
1989: Manfred Volm; M Bak; Jürgen Mattern
Intrinsic multidrug resistance in human lung carcinomas grown in nude mice.
Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al] 1989;165(7):524-6.
1989: M Bak; Jürgen Mattern; Manfred Volm
Comparative histopathology of human epidermoid lung carcinoma xenografts.
Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al] 1989;165(7):485-6.
1989: Eric W Hahn; Gerd Wolber; M Bak; K H Hoever; L Gerlach; Manfred Volm; W J Lorenz
Response of the R3327-AT1 Dunning prostate tumor to fast neutrons and cobalt-60.
Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al] 1989;165(4):283-5.
1989: J Sonka; U Schossig; M Vogt-Schaden; Manfred Volm
Initial and early effects of adriamycin in murine sarcoma 180 cannot be restored in a resistant subline by increasing the uptake and external concentration of the drug.
Cancer chemotherapy and pharmacology 1989;24(1):33-40.
1989: Manfred Volm; T Efferth; M Bak; J Mattern
Detection of drug resistance in human ovarian carcinoma.
Archives of gynecology and obstetrics 1989;244(2):123-8.
1989: Manfred Volm; M Bak; T Efferth; Jürgen Mattern
Induced multidrug resistance in murine leukemia L1210 and associated changes in a surface-membrane glycoprotein.
Journal of cancer research and clinical oncology 1989;115(1):17-24.
1988: T Efferth; Manfred Volm
Rapid detection assays for multidrug resistance.
Arzneimittel-Forschung 1988;38(12):1771-4.
1988: Manfred Volm; M Bak; T Efferth; Jürgen Mattern
Induced multidrug-resistance in murine sarcoma 180 cells grown in vitro and in vivo and associated changes in expression of multidrug-resistance DNA-sequences and membrane glycoproteins.
Anticancer research 1988;8(6):1169-78.
1988: K C Grancharov; M Koch; Manfred Volm; G F Kolar
Synthesis and cytotoxic effects of hydroxymethyl-3-pyridyl- and 2-chloro-5-pyridyltriazene derivatives.
Cancer letters 1988;41(3):271-9.
1988: Manfred Volm; M Bak; Jürgen Mattern
Intrinsic drug resistance in a human lung carcinoma xenograft is associated with overexpression of multidrug-resistance DNA-sequences and of plasma membrane glycoproteins.
Arzneimittel-Forschung 1988;38(8):1189-93.
1988: Jürgen Mattern; M Bak; K H Hoever; Manfred Volm
Development of drug resistance in a human epidermoid lung carcinoma xenograft line.
British journal of cancer 1988;58(1):30-3.
1988: Manfred Volm; M Bak; T Efferth; B Lathan; Jürgen Mattern
Immunocytochemical detection of a resistance-associated glycoprotein in tissue culture cells, ascites tumors and human tumor xenografts by Mab 265/F4.
Anticancer research 1988;8(4):531-5.
1988: Manfred Volm; M Bak; Eric W Hahn; Jürgen Mattern; E Weber
DNA and S-phase distribution and incidence of metastasis in human primary lung carcinoma.
Cytometry 1988;9(2):183-8.
1988: Manfred Volm; P Drings; Eric W Hahn; Jürgen Mattern
Prediction of the clinical chemotherapeutic response of stage III lung adenocarcinoma patients by an in vitro short term test.
British journal of cancer 1988;57(2):198-200.
1988: Manfred Volm; Jürgen Mattern; T Müller; P Drings
Flow cytometry of epidermoid lung carcinomas: relationship of ploidy and cell cycle phases to survival. A five-year follow up study.
Anticancer research 1988;8(1):105-12.
1987: Manfred Volm; P Drings; W Kleine; Jürgen Mattern
Flow cytometry as a tool for the prognostic assessment of patients with lung and ovarian carcinomas.
Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al] 1987;163(12):791-4.
1987: Manfred Volm; Jürgen Mattern
Clinical prognostic relevance of growth of human adenocarcinomas of the lung in nude mice.
Anticancer research 1987;7(6):1129-32.
1987: Jürgen Mattern; M Bak; Manfred Volm
Occurrence of a multidrug-resistant phenotype in human lung xenografts.
British journal of cancer 1987;56(4):407-11.
1987: M Bak; J Mattern; Manfred Volm
Maintenance of morphology and tumour marker production in human epidermoid lung carcinoma xenografts.
In vivo (Athens, Greece) 1987;1(5):319-26.
1987: Manfred Volm; T Efferth; A Günther; B Lathan
Detection of murine S180 cells expressing a multidrug resistance phenotype using different in vitro test systems and a monoclonal antibody.
Arzneimittel-Forschung 1987;37(7):862-7.
1987: Manfred Volm; J Mattern; M Vogt-Schaden; K Wayss
Flow cytometric analysis of primary lung carcinomas and their lymph node metastases.
Anticancer research 1987;7(1):71-6.
1987: J Mattern; K Wayss; Manfred Volm
Sensitivity of human non-small cell lung cancer xenografts to cyclophosphamide and cisplatin.
In vivo (Athens, Greece) 1987;1(1):23-6.
1986: Manfred Volm; P Drings; J Mattern; J Sonka; I Vogt-Moykopf; K Wayss
Relevance of DNA-fluorimetry and short-term resistance testing for adjuvant treatment of non-small cell lung carcinomas.
Anticancer research 1986;6(5):931-4.
1985: Manfred Volm; P Drings; J Mattern; J Sonka; I Vogt-Moykopf; K Wayss
Prognostic significance of DNA patterns and resistance-predictive tests in non-small cell lung carcinoma.
Cancer 1985;56(6):1396-403.
1985: J Sonka; M Stöhr; M Vogt-Schaden; Manfred Volm
Anthracycline resistance and consequences of the in situ-in vitro transfer.
Cytometry 1985;6(5):437-44.
1985: Manfred Volm; J Mattern; J Sonka; M Vogt-Schaden; K Wayss
DNA distribution in non-small-cell lung carcinomas and its relationship to clinical behavior.
Cytometry 1985;6(4):348-56.
1985: J Mattern; S Jäger; J Sonka; K Wayss; Manfred Volm
Growth of human bronchial carcinomas in nude mice.
British journal of cancer 1985;51(2):195-200.
1983: J Sonka; M Stöhr; M Vogt-Schaden; Manfred Volm
Isopycnic density-gradient centrifugation: a separation parameter which improves flow cytometric measurements on heterogeneous tumors.
Cytometry 1983;4(2):141-9.